MorphoSys collaborates with Genesis Research on novel target molecule

MorphoSys has entered into a therapeutic research collaboration with Genesis Research and Development Corporation to investigate a target molecule implicated in various autoimmune and bone-related diseases.

The partnership will mean a continuation in the use of Human Combinatorial Antibody Library (HuCAL)-based antibodies originally generated by the MorphoSys business unit - AbD Serotec - against the human fibroblast growth factor receptor FGFR5 for target validation and pre-clinical studies as part of its proprietary Zyrogen programme.

Genesis is investigating the development of therapeutic antibodies specific for the target molecule FGFR5 - a cell surface protein expressed by stromal cells of the hemopoietic system, was originally identified by Genesis from its proprietary EST databases.

Genesis has carried out extensive studies to characterise the molecule's interactions with different cell types and tissues, suggesting that it is a therapeutic target for diseases such as osteoporosis, systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis.

With the signing of this agreement, Genesis will continue to extend its strong patent position around this molecule using the HuCAL antibodies and will further validate its approach through in vitro and in vivo studies as a necessary prelude to a clinical development programme.

"The collaboration with Genesis provides us with access to an innovative and scientifically attractive target molecule which may lead to lucrative future commercial opportunities for MorphoSys," said Dr Simon Moroney, chief executive officer of MorphoSys. "At the same time, it is a further example of the synergies arising between our two business segments, as satisfied AbD Serotec customers decide to partner with MorphoSys for the development of their therapeutic or diagnostic projects."

MorphoSys was granted a fifth US patent stemming from MorphoSys' base HuCAL patent family, providing extended protection to MorphoSys' core technology in September 2007. The new patent captures HuCAL's modular design at the DNA level, providing solid product claim protection in the US.